Caricamento...
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in...
Salvato in:
| Pubblicato in: | Ther Adv Urol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896861/ https://ncbi.nlm.nih.gov/pubmed/29662544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287217713902 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|